| Today's Big NewsFeb 22, 2023 |
|
Tuesday, March 14, 2023 | 2pm ET / 11am PT Join this webinar to hear industry experts across the clinical research space share their perspectives on inefficiencies in the current clinical research space, how to prioritize change, where to begin, how to measure success, and considerations when evaluating and selecting enabling technology. Register now.
|
|
| By Angus Liu Eli Lilly said it has resolved a months-long shortage of popular diabetes med Mounjaro by clearing all backorders, although the FDA remains cautious about the situation. |
|
|
|
By Annalee Armstrong After ending all cardiology work in the wake of a failed phase 3 trial, Quantum Genomics is now reorganizing its board of directors, restructuring staff and again conducting a strategic review. |
By Andrea Park A potential import ban on the Apple Watch is still on the table as an International Trade Commission ruling against the technology cleared presidential review this month. |
By Fraiser Kansteiner The FDA has cleared Teva’s Austedo extended-release tablets in 6-, 12- and 24-mg doses, teeing up a once-daily formulation of the drug that—for the first time—can also be taken without food. The new formulation boasts therapeutic equivalence to its twice-a-day counterpart, which was first approved back in 2017. |
|
Tuesday, March 21, 2023 | 11am ET / 8am PT Today’s clinical trials are longer and more complex than ever. Sponsors, sites, and patients need technology that is practical, easy to use, and strengthens studies’ scientific integrity. This webinar will explore how approaches from B2B and consumer technologies can be leveraged to streamline processes, deliver quality outcomes data, and more. Register now.
|
|
By Andrea Park Hyperfine has gotten the green light to take its talents to the EU—but whether the portable MRI tech maker will actually make the transatlantic trip is another story. |
By Max Bayer Biotechs are pleading for help to develop new treatments for long COVID, as the U.S. moves past the pandemic. Patients and advocates worry they're being left behind. |
By Fraiser Kansteiner Drug manufacturer National Resilience is laying off about 213 employees in Boston, a company spokesperson confirmed via email. The staff reduction is a “function of transition” tied to the end of a manufacturing contract with Sanofi, Resilience chief Rahul Singhvi told Fierce Pharma. |
By James Waldron Not content with overseeing his ever-expanding ‘vant’ empire, Roivant founder Vivek Ramaswamy has set his sights on a far more ambitious goal: the White House. |
By Andrea Park A collaboration between Ascensia Diabetes Care and the Snaq app-based platform is giving new meaning to the phrase, “Say cheese!” |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
Fierce podcastsDon't miss an episode |
| In this week's episode of "Podnosis," we talk about a new report by the Private Equity Stakeholder Project on private equity in rural settings. We also talk with Margaret-Mary Wilson, M.D., about how her lived experience has influenced her career journey. |
|
|---|
|
|
|
Wednesday, March 29, 2023 | 2pm ET / 11 am PT Attendees will come away with a deeper understanding of how genetic counseling and genetic services workflows can help biopharma organizations more effectively identify patients that qualify for their clinical trials and/or commercial therapeutics, the value of customized genetic services workflows in optimizing clinical trial/sponsored testing program ROI, and more. Register now.
|
|
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
